Achieve life sciences announces start of phase 3 orca-2 clinical trial evaluating cytisinicline for smoking cessation

Seattle and vancouver, b.c., oct. 7, 2020 /prnewswire/ -- achieve life sciences, inc. (nasdaq: achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced initiation...
ACHV Ratings Summary
ACHV Quant Ranking